Credit rating agency ICRA predicts that the revenues of 25 Indian pharmaceutical companies, which account for 60% of the Indian pharmaceutical industry's total revenues, will expand by 9-11% in FY24, compared to 10% in the previous year. The operating profit margin (OPM) is projected to improve to 22-23% in FY24, compared to 20.7% in FY2023.
